IQ-AI Ltd
OTC:IQAIF
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JE |
|
IQ-AI Ltd
LSE:IQAI
|
2m GBP |
Loading...
|
|
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
33.2B USD |
Loading...
|
|
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD |
Loading...
|
|
| AU |
|
Pro Medicus Ltd
ASX:PME
|
18.5B AUD |
Loading...
|
|
| JP |
|
M3 Inc
TSE:2413
|
1.3T JPY |
Loading...
|
|
| US |
|
Doximity Inc
NYSE:DOCS
|
7.1B USD |
Loading...
|
|
| SE |
|
Sectra AB
STO:SECT B
|
41.7B SEK |
Loading...
|
|
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.6B USD |
Loading...
|
|
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
23.7B CNY |
Loading...
|
|
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
280.9B INR |
Loading...
|
|
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR |
Loading...
|
Market Distribution
| Min | -49.3% |
| 30th Percentile | -0.8% |
| Median | -0.3% |
| 70th Percentile | 0.1% |
| Max | 830.3% |
Other Profitability Ratios
IQ-AI Ltd
Glance View
IQ-AI Ltd. is a holding company, which engages in the provision of clinical treatments to patients in the field of medical imaging diagnostics. The firm provides health care technology solutions to the artificial intelligence (AI) medical imaging market. Through its subsidiary, StoneChecker Software Ltd, It offers medical imaging software for urolithiasis that analyses and presents stone metrics, including stone size, volume, density, skin to stone distance, and stone architecture through TexRAD analysis within the healthcare information technology (IT) systems. Through its subsidiary, Imaging Biometrics, LLC, It specializes in the design and manufacture of visualization tools, the application of machine learning and AI software solutions, and the development and clinical testing of imaging endpoints and biomarkers. Its portfolio consists of IB Neuro and IB Diffusion that are used in treatment of brain tumors, strokes and pathologies.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for IQ-AI Ltd is -77.5%, which is above its 3-year median of -90.2%.
Over the last 3 years, IQ-AI Ltd’s Net Margin has increased from -147.9% to -77.5%. During this period, it reached a low of -147.9% on May 30, 2021 and a high of -77.5% on Jul 30, 2024.
